BLIS Technologies (NZSE:BLT) Investments And Advances : NZ$0.00 Mil (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is BLIS Technologies Investments And Advances?

BLIS Technologies's Investments And Advances for the quarter that ended in Mar. 2024 was NZ$0.00 Mil.

BLIS Technologies Investments And Advances Historical Data

The historical data trend for BLIS Technologies's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BLIS Technologies Investments And Advances Chart

BLIS Technologies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Investments And Advances

Get a 7-Day Free Trial

BLIS Technologies Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Investments And Advances	Get a 7-Day Free Trial															-	-	-	-	-

BLIS Technologies Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

BLIS Technologies (NZSE:BLT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BLIS Technologies Ltd (NZSE:BLT) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

N/A

Address

442 Moray Place, Ground Floor, Dunedin, OTA, NZL, 9016

Website

https://www.blis.co.nz

BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets two strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 both of which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).